Literature DB >> 28560208

Challenges of Achieving Tuberculosis Elimination by 2050: A Need for More Attention in the TB Control Program in Iran.

Salman Khazaei1, Shahab Rezaeian2.   

Abstract

Entities:  

Year:  2017        PMID: 28560208      PMCID: PMC5442290     

Source DB:  PubMed          Journal:  Iran J Public Health        ISSN: 2251-6085            Impact factor:   1.429


× No keyword cloud information.

Dear Editor-in-Chief

The epidemic of HIV and tuberculosis (TB) put a high socioeconomic burden on the communities. Despite progress in the TB program indexes in recent years, an increasing trend in HIV remains as a global challenge within and between countries. This letter aims to highlight a number of issues, which may help policymakers to make better policies to control the morbidity and mortality. First, based on international reports of the WHO data for countries from 1990–2014 (Fig. 1), the estimated prevalence of TB from 1995 to 2010 in Iran was decreasing, after that there is an increasing trend for prevalence of TB (Annual Percent Change=2.65) (Table 1). In addition, the national studies have also showed an increasing trend in the TB incidence (1).
Fig. 1:

Trend and Annual Percent change (APC) for estimated prevalence of TB in Iran from 1990–2014

Table 1:

Estimated prevalence of TB (all forms) per 100,000 populations in Iran during 1990–2014

Year199019952000200520102014
Prevalence50 (25–82)54 (27–89)39 (20–64)31 (16–51)30 (15–50)33 (17–55)
Trend and Annual Percent change (APC) for estimated prevalence of TB in Iran from 1990–2014 Estimated prevalence of TB (all forms) per 100,000 populations in Iran during 1990–2014 On the other hand, despite raised awareness about the HIV/AIDS in Iran some studies have shown an increasing trend in the HIV prevalence in the community and in the high-risk groups. A modeling study has shown an upward trend in the number of HIV infections in general population (2). Another study to determine the trend of HIV/AIDS prevalence in prisons during a 13-year period showed an increasing trend in the HIV infection during 2002–5 in Iranian prisons, but with a downward trend totally (3). Nevertheless, the prevalence of HIV was significantly higher in the prisons (3) where the high prevalence of TB has been reported. In other word, an 8-year study revealed an increasing trend in the TB incidence in Iranian prisons (4). Another important issue, as a complicated factor to control TB, is related to the neighborhood countries of Iran. Through the periods of Iraq and Afghanistan war and now, Iran was a host country for the refugees who were susceptible to the disease. Accordingly, the increasing immigration trends could influence the prevalence and transmission patterns of TB in the host country (5). As a result, the mentioned issues, which preclude any possibility of achieving TB elimination by 2050 need to be considered as, key factors affecting on TB prevention program.
  3 in total

1.  Forecast analysis of the incidence of tuberculosis in the province of Quebec.

Authors:  Alexander Klotz; Abdoulaye Harouna; Andrew F Smith
Journal:  BMC Public Health       Date:  2013-04-27       Impact factor: 3.295

2.  Trend of HIV/AIDS Prevalence and Related Interventions Administered in Prisons of Iran -13 Years' Experience.

Authors:  Mohammad Shahbazi; Marzieh Farnia; Khaled Rahmani; Ghobad Moradi
Journal:  Iran J Public Health       Date:  2014-04       Impact factor: 1.429

3.  Predicting the Incidence of Smear Positive Tuberculosis Cases in Iran Using Time Series Analysis.

Authors:  Mahmood Moosazadeh; Narges Khanjani; Mahshid Nasehi; Abbas Bahrampour
Journal:  Iran J Public Health       Date:  2015-11       Impact factor: 1.429

  3 in total
  1 in total

1.  Spatio-temporal epidemiology of the tuberculosis incidence rate in Iran 2008 to 2018.

Authors:  Behzad Kiani; Amene Raouf Rahmati; Robert Bergquist; Soheil Hashtarkhani; Neda Firouraghi; Nasser Bagheri; Elham Moghaddas; Alireza Mohammadi
Journal:  BMC Public Health       Date:  2021-06-07       Impact factor: 3.295

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.